deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03128034

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

Sponsor: Fred Hutchinson Cancer Center

Conditions Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome With Excess Blasts Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia Recurrent Mixed Phenotype Acute Leukemia Refractory Acute Lymphoblastic Leukemia Refractory Acute Myeloid Leukemia Refractory Mixed Phenotype Acute Leukemia
Interventions Biospecimen Collection Cyclosporine Fludarabine Phosphate Mycophenolate Mofetil Peripheral Blood Stem Cell Transplantation Pretargeted Radioimmunotherapy Single Photon Emission Computed Tomography Total-Body Irradiation
Updated 32 times since 2017 Last updated: Dec 17, 2025 Started: Oct 24, 2017 Primary completion: Jun 30, 2027 Completion: Mar 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia and is currently actively recruiting participants. Fred Hutchinson Cancer Center leads this study, which shows 32 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshot~Jul 2025 – ~Jan 2026 · 6 months · monthly snapshot~Jan 2026 – present · 8 months · monthly snapshot

Change History

32 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Jul 2025 — Jan 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Apr 2025 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE1/PHASE2

    Status: Suspended → Recruiting

  5. Feb 2025 — Mar 2025 [monthly]

    Suspended PHASE1/PHASE2

▶ Show 27 earlier versions

  1. Sep 2024 — Feb 2025 [monthly]

    Suspended PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Feb 2024 — Jul 2024 [monthly]

    Suspended PHASE1_PHASE2

  4. Nov 2023 — Feb 2024 [monthly]

    Suspended PHASE1_PHASE2

  5. Jul 2023 — Nov 2023 [monthly]

    Suspended PHASE1_PHASE2

  6. May 2023 — Jul 2023 [monthly]

    Suspended PHASE1_PHASE2

  7. Mar 2023 — May 2023 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  8. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2021 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  15. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Suspended → Recruiting

  16. Apr 2020 — Jun 2020 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  17. Sep 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  18. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  19. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  20. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  21. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  22. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  23. Dec 2017 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  24. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Sep 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    Status: Recruiting → Not Yet Recruiting

  26. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  27. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations